Encision Reports Fourth Quarter Fiscal Year 2025 Results
Encision Inc. (OTC PINK:ECIA), a medical device company specializing in Active Electrode Monitoring (AEM®) Technology, reported its fiscal year 2025 results. The company posted Q4 net revenue of $1.52 million with a quarterly net loss of $47,000 ($(0.00) per share), compared to a net loss of $337,000 ($(0.03) per share) in Q4 2024.
For fiscal year 2025, Encision reported total net revenue of $6.56 million, comprising $6.22 million in product revenue and $0.34 million in service revenue. The company's net loss improved to $0.22 million ($(0.02) per share) from $0.69 million ($(0.06) per share) in FY2024. Notably, gross margin on product revenue increased to 53.8% in FY2025 from 47.6% in FY2024, driven by lower material costs and improved operational efficiency.
Encision Inc. (OTC PINK:ECIA), azienda di dispositivi medici specializzata nella tecnologia Active Electrode Monitoring (AEM®), ha comunicato i risultati dell'anno fiscale 2025. La società ha registrato un fatturato netto nel quarto trimestre di 1,52 milioni di dollari con una perdita netta trimestrale di 47.000 dollari ($(0,00) per azione), rispetto a una perdita netta di 337.000 dollari ($(0,03) per azione) nel quarto trimestre 2024.
Per l'anno fiscale 2025, Encision ha riportato un fatturato netto totale di 6,56 milioni di dollari, composto da 6,22 milioni di dollari di ricavi da prodotti e 0,34 milioni di dollari da servizi. La perdita netta dell'azienda è migliorata a 0,22 milioni di dollari ($(0,02) per azione) rispetto a 0,69 milioni di dollari ($(0,06) per azione) nell'anno fiscale 2024. In particolare, il margine lordo sui ricavi da prodotti è salito al 53,8% nell'anno fiscale 2025 rispetto al 47,6% del 2024, grazie a una riduzione dei costi dei materiali e a una maggiore efficienza operativa.
Encision Inc. (OTC PINK:ECIA), una empresa de dispositivos médicos especializada en la tecnología Active Electrode Monitoring (AEM®), informó sus resultados del año fiscal 2025. La compañía registró ingresos netos del cuarto trimestre por 1,52 millones de dólares con una pérdida neta trimestral de 47,000 dólares ($(0,00) por acción), en comparación con una pérdida neta de 337,000 dólares ($(0,03) por acción) en el cuarto trimestre de 2024.
Para el año fiscal 2025, Encision reportó ingresos netos totales de 6,56 millones de dólares, compuestos por 6,22 millones en ingresos por productos y 0,34 millones en ingresos por servicios. La pérdida neta de la empresa mejoró a 0,22 millones de dólares ($(0,02) por acción) desde 0,69 millones ($(0,06) por acción) en el año fiscal 2024. Destaca que el margen bruto sobre los ingresos por productos aumentó a 53,8% en el año fiscal 2025 desde el 47,6% en 2024, impulsado por menores costos de materiales y una mayor eficiencia operativa.
Encision Inc. (OTC PINK:ECIA)� 액티� 전극 모니터링(AEM®) 기술� 전문으로 하는 의료기기 회사�, 2025 회계연도 실적� 발표했습니다. 회사� 4분기 순매� 152� 달러� 기록했으�, 분기 순손실은 47,000달러($(0.00) 주당)�, 2024� 4분기 순손� 337,000달러($(0.03) 주당)와 비교� 개선되었습니�.
2025 회계연도 기준으로 Encision은 � 순매� 656� 달러� 보고했으�, � � 제품 매출� 622� 달러, 서비� 매출� 34� 달러� 차지했습니다. 회사� 순손실은 2024 회계연도� 69� 달러($(0.06) 주당)에서 22� 달러($(0.02) 주당)� 개선되었습니�. 특히, 제품 매출� 대� � 마진은 원자� 비용 감소와 운영 효율� 향상� 힘입� 2024� 47.6%에서 2025� 53.8%� 상승했습니다.
Encision Inc. (OTC PINK:ECIA), une entreprise de dispositifs médicaux spécialisée dans la technologie de surveillance active des électrodes (AEM®), a publié ses résultats pour l'exercice 2025. La société a enregistré un chiffre d'affaires net au quatrième trimestre de 1,52 million de dollars avec une perte nette trimestrielle de 47 000 dollars ($(0,00) par action), contre une perte nette de 337 000 dollars ($(0,03) par action) au quatrième trimestre 2024.
Pour l'exercice 2025, Encision a déclaré un chiffre d'affaires net total de 6,56 millions de dollars, comprenant 6,22 millions de dollars de revenus produits et 0,34 million de dollars de revenus de services. La perte nette de l'entreprise s'est améliorée à 0,22 million de dollars ($(0,02) par action) contre 0,69 million de dollars ($(0,06) par action) en 2024. Notamment, la marge brute sur les revenus produits a augmenté à 53,8 % en 2025 contre 47,6 % en 2024, grâce à une baisse des coûts des matériaux et à une meilleure efficacité opérationnelle.
Encision Inc. (OTC PINK:ECIA), ein Medizintechnikunternehmen, das auf Active Electrode Monitoring (AEM®) Technologie spezialisiert ist, veröffentlichte seine Ergebnisse für das Geschäftsjahr 2025. Das Unternehmen erzielte im vierten Quartal einen Nettoumsatz von 1,52 Millionen US-Dollar bei einem vierteljährlichen Nettoverlust von 47.000 US-Dollar ($(0,00) je Aktie), verglichen mit einem Nettoverlust von 337.000 US-Dollar ($(0,03) je Aktie) im vierten Quartal 2024.
Für das Geschäftsjahr 2025 meldete Encision einen Gesamtnettoumsatz von 6,56 Millionen US-Dollar, bestehend aus 6,22 Millionen US-Dollar Produktumsatz und 0,34 Millionen US-Dollar Serviceumsatz. Der Nettoverlust des Unternehmens verbesserte sich auf 0,22 Millionen US-Dollar ($(0,02) je Aktie) gegenüber 0,69 Millionen US-Dollar ($(0,06) je Aktie) im Geschäftsjahr 2024. Bemerkenswert ist, dass die Bruttomarge auf Produktumsätze auf 53,8 % im Geschäftsjahr 2025 stieg, verglichen mit 47,6 % im Jahr 2024, was auf geringere Materialkosten und verbesserte operative Effizienz zurückzuführen ist.
- None.
- Total revenue slightly declined to $6.56M from $6.59M year-over-year
- Product revenue decreased to $6.22M from $6.43M
- Operating loss of $171,980 for FY2025
- Line of credit increased to $395,964 from $0 in previous year
- Quarterly revenue declined to $1.52M from $1.53M year-over-year
BOULDER, CO / / July 11, 2025 / Encision Inc. (OTC PINK:ECIA), a medical device company that owns the patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal year ended March 31, 2025.
The Company posted quarterly net revenue of
The Company posted annual product net revenue of
"We made progress in improving our gross margins and managing expenses in fiscal 2025," said Gregory Trudel, President & CEO of Encision. "While top-line revenue was relatively flat, we saw improvements in service revenue and operational efficiency. We remain committed to advancing our technology and bringing innovative surgical safety solutions to market."
Encision Inc. designs and markets a portfolio of high-performance surgical instrumentation that delivers advances in patient safety with AEM technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures. For additional information about all our products, please visit .
In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to develop new or enhanced products and have such products accepted in the market, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delays in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2025, and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.
CONTACT:
Brandon Shepard
Encision Inc.
303-444-2600
Encision Inc.
Balance Sheets
March 31, 2025 | March 31, 2024 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash | $ | 257,433 | $ | 42,509 | ||||
Accounts receivable | 786,471 | 891,129 | ||||||
Inventories | 1,483,182 | 1,402,338 | ||||||
Prepaid expenses | 85,679 | 90,298 | ||||||
Total current assets | 2,612,765 | 2,426,274 | ||||||
Equipment: | ||||||||
Furniture, fixtures and equipment, at cost | 2,585,446 | 2,627,726 | ||||||
Accumulated depreciation | (2,340,689 | ) | (2,373,722 | ) | ||||
Equipment, net | 244,757 | 254,004 | ||||||
Right of use asset, net | 568,395 | 900,787 | ||||||
Patents, net | 171,890 | 164,010 | ||||||
Other assets | 72,892 | 65,641 | ||||||
TOTAL ASSETS | $ | 3,670,699 | $ | 3,810,716 | ||||
LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 346,900 | $ | 346,049 | ||||
Line of credit | 395,964 | -- | ||||||
Secured notes | 44,128 | 47,194 | ||||||
Accrued compensation | 180,850 | 184,913 | ||||||
Deferred Revenue | 17,401 | -- | ||||||
Other accrued liabilities | 160,274 | 119,804 | ||||||
Accrued lease liability | 430,398 | 370,377 | ||||||
Total current liabilities | 1,575,915 | 1,068,337 | ||||||
Long-term liability: | ||||||||
Secured notes | 177,470 | 219,021 | ||||||
Accrued lease liability | 266,212 | 696,610 | ||||||
Total liabilities | 2,019,597 | 1,983,968 | ||||||
Commitments and contingencies (Note 4) | ||||||||
Shareholders' equity: | ||||||||
Preferred stock, no par value: 10,000,000 shares authorized; none issued and outstanding | -- | -- | ||||||
Common stock and additional paid-in capital, no par value: 100,000,000 shares authorized; 11,879,645 issued and outstanding at March 31, 2025 and 11,858,627 at March 31, 2024 | 24,416,347 | 24,371,795 | ||||||
Accumulated (deficit) | (22,765,245 | ) | (22,545,047 | ) | ||||
Total shareholders' equity | 1,651,102 | 1,826,748 | ||||||
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 3,670,699 | $ | 3,810,716 |
Encision Inc.
Statements of Operations
Years Ended | March 31, 2025 | March 31, 2024 | ||||||
NET REVENUE: | ||||||||
Product | $ | 6,217,687 | $ | 6,431,969 | ||||
Service | 337,628 | 153,913 | ||||||
Total revenue | 6,555,315 | 6,585,882 | ||||||
COST OF REVENUE: | ||||||||
Product | 2,873,588 | 3,370,855 | ||||||
Service | 170,441 | 79,065 | ||||||
Total cost of revenue | 3,044,029 | 3,449,920 | ||||||
GROSS PROFIT | 3,511,286 | 3,135,962 | ||||||
OPERATING EXPENSES: | ||||||||
Sales and marketing | 1,689,503 | 1,634,124 | ||||||
General and administrative | 1,400,611 | 1,520,727 | ||||||
Research and development | 593,152 | 621,894 | ||||||
Total operating expenses | 3,683,266 | 3,776,745 | ||||||
OPERATING (LOSS) | (171,980 | ) | (640,783 | ) | ||||
OTHER (EXPENSE): | ||||||||
Interest expense, net | (43,723 | ) | (62,373 | ) | ||||
Other income, (expense) net | (4,495 | ) | 11,373 | |||||
Interest expense and other income, expense, net | (48,218 | ) | (51,000 | ) | ||||
(LOSS) BEFORE PROVISION FOR INCOME TAXES | (220,198 | ) | (691,783 | ) | ||||
Provision for income taxes | -- | -- | ||||||
NET (LOSS) | $ | (220,198 | ) | $ | (691,783 | ) | ||
Net (loss) per share-basic and diluted | $ | (0.02 | ) | $ | (0.06 | ) | ||
Weighted average shares-basic and diluted | 11,879,645 | 11,770,391 | ||||||
Encision Inc.
Statements of Cash Flows
Years Ended | March 31, 2025 | March 31, 2024 | ||||||
Cash flows provided by (used in) operating activities: | ||||||||
Net (loss) | (220,198 | ) | $ | (691,783 | ) | |||
Adjustments to reconcile net (loss) income to net cash (used in) operating activities: | ||||||||
Depreciation and amortization | 81,393 | 85,218 | ||||||
Stock-based compensation expense related to stock options | 46,001 | 53,552 | ||||||
Provision for inventory obsolescence | 4,920 | 12,000 | ||||||
Change in operating assets and liabilities: | ||||||||
Right of use asset, net | (37,985 | ) | 68,710 | |||||
Accounts receivable | 104,658 | 29,592 | ||||||
Inventories | (85,764 | ) | 484,866 | |||||
Prepaid expenses and other assets | (2,632 | ) | 6,728 | |||||
Accounts payable | 18,252 | 93,092 | ||||||
Accrued compensation and other accrued liabilities | 36,407 | 2,414 | ||||||
Net cash provided by (used in) operating activities | (54,948 | ) | 144,389 | |||||
Cash flows (used in) investing activities: | ||||||||
Acquisition of property and equipment | (54,415 | ) | (12,050 | ) | ||||
Patent costs | (25,610 | ) | (24,773 | ) | ||||
Net cash (used in) investing activities | (80,025 | ) | (36,823 | ) | ||||
Cash flows provided by (used in) financing activities: | ||||||||
Borrowings from (paydown of) credit facility, net change | 395,964 | (177,402 | ) | |||||
Borrowings from (paydown of) secured notes | (44,618 | ) | (46,788) | |||||
Net proceeds (payments) from exercise of stock options | (1,449 | ) | (29,833 | ) | ||||
Net cash provided by (used in) financing activities | 349,897 | (254,023 | ) | |||||
Net (decrease) in cash | 214,924 | (146,457 | ) | |||||
Cash, beginning of fiscal year | 42,509 | 188,966 | ||||||
Cash, end of fiscal year | $ | 257,433 | $ | 42,509 | ||||
Supplemental disclosure of non-cash investing activity information: | ||||||||
Supplemental disclosures of cash flow information: | ||||||||
Cash paid during the year for interest | $ | 43,723 | $ | 62,373 |
SOURCE: Encision, Inc.
View the original on ACCESS Newswire